Carly Robinson

Cooley advised Scorpion Therapeutics in its collaboration agreement with AstraZeneca to discover, develop and commercialize precision medicines against previously hard-to-target cancer proteins, with the potential to transform oncology treatment.

Under the terms of the collaboration agreement, Scorpion will receive an upfront cash payment of $75 million and is eligible to receive additional success-based payments in the form of option fees and milestone payments, as well as tiered royalties on net sales ranging from mid-single digit to low-double digits. In the event Scorpion opts into co-developing and co-promoting a nominated program, Scorpion will participate in the operating costs and be entitled to a proportionate share of the economics in the US, subject to certain adjustments.

Cooley advised Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, on its license, development and commercialization agreement with Bristol Myers Squibb for its TCR bispecific candidate, IMA401. Lawyers Ken Krisko, Carly Robinson, Brian Stalter and Stephanie Palmer led the Cooley team advising Immatics.

Cooley advised Prothena, a late-stage clinical company with a robust pipeline of novel investigational therapeutics, on its agreement to sell its clinical-stage antibody PRX004 and broader amyloid transthyretin (ATTR) amyloidosis program to Novo Nordisk for $1.2 billion. Partners Marya Postner and Barbara Borden led the Cooley team advising Prothena.

Cooley advised ARCH Venture Partners, which co-led a $1 billion Series A funding round in Xaira Therapeutics. Partners Colleen Badgley, Danielle Naftulin and Dave Peinsipp led the Cooley team advising ARCH, a venture capital firm catalyzing discoveries that prevent, detect and cure disease.

Cooley advised Autolus – a clinical-stage biopharmaceutical company developing next-generation programmed T-cell therapies – on its strategic collaboration with BioNTech, an immunotherapy company pioneering novel therapies for cancer and other serious diseases, to advance both companies’ autologous CAR-T programs toward commercialization, as well as a $350 million underwritten offering.